Quantisnow Logo
Dashboard

Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

$MRVI
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $MRVI alert in real time by email
SC 13G/A 1 d873306dsc13ga.htm SC 13G/A SC 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)*

 

 

Maravai LifeSciences Holdings, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.01 per share

(Title of Class of Securities)

56600D 107

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

 

 

Check the Appropriate Box to Designate the Rule Pursuant to Which this Schedule Is Filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

1.   

Names of Reporting Persons

 

Maravai Life Sciences Holdings 2, LLC

2.   

Check The Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  (b) ☐

 

3.   

SEC Use Only

 

4.   

Citizenship or Place of Organization

 

Delaware

Number of Shares Beneficially  Owned By Each Reporting Person

With

    5.   

Sole Voting Power

 

0

   6.   

Shared Voting Power

 

20,150,005

   7.   

Sole Dispositive Power

 

0

   8.   

Shared Dispositive Power

 

20,150,005

9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

20,150,005

10.   

Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

 

☐

11.   

Percent of Class Represented By Amount in Row (9)

 

7.98%(1)

12.   

Type of Reporting Person (See Instructions)

 

OO

 

(1)

Calculated based on 141,843,505 shares of the Issuer’s Class A common stock, par value $0.01 per share (“Class A Common Stock”), outstanding as of November 7, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2024, as increased by an additional 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 units of Maravai Topco Holdings, LLC (“Common Units”) (together with an equal number of shares of the Issuer’s Class B common stock, par value $0.01 per share (“Class B Common Stock”)).

1.   

Names of Reporting Persons

 

Maravai Life Sciences Holdings, LLC

2.   

Check The Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  (b) ☐

 

3.   

SEC Use Only

 

4.   

Citizenship or Place of Organization

 

Delaware

Number of Shares Beneficially  Owned By Each Reporting Person

With

    5.   

Sole Voting Power

 

0

   6.   

Shared Voting Power

 

110,684,080

   7.   

Sole Dispositive Power

 

0

   8.   

Shared Dispositive Power

 

110,684,080

9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

110,684,080(1)

10.   

Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

 

☐

11.   

Percent of Class Represented By Amount in Row (9)

 

43.83%(2)

12.   

Type of Reporting Person (See Instructions)

 

OO

 

(1)

Includes 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).

(2)

Calculated based on 141,843,505 shares of Class A Common Stock outstanding as of November 7, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024, as increased by an additional 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).

1.   

Names of Reporting Persons

 

GTCR Fund XI/C LP

2.   

Check The Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  (b) ☐

 

3.   

SEC Use Only

 

4.   

Citizenship or Place of Organization

 

Delaware

Number of Shares Beneficially  Owned By Each Reporting Person

With

    5.   

Sole Voting Power

 

0

   6.   

Shared Voting Power

 

20,150,005

   7.   

Sole Dispositive Power

 

0

   8.   

Shared Dispositive Power

 

20,150,005

9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

20,150,005

10.   

Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

 

☐

11.   

Percent of Class Represented By Amount in Row (9)

 

7.98%(1)

12.   

Type of Reporting Person (See Instructions)

 

PN

 

(1)

Calculated based on 141,843,505 shares of Class A Common Stock outstanding as of November 7, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024, as increased by an additional 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).

1.   

Names of Reporting Persons

 

GTCR Fund XI/B LP

2.   

Check The Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  (b) ☐

 

3.   

SEC Use Only

 

4.   

Citizenship or Place of Organization

 

Delaware

Number of Shares Beneficially  Owned By Each Reporting Person

With

    5.   

Sole Voting Power

 

0

   6.   

Shared Voting Power

 

110,684,080

   7.   

Sole Dispositive Power

 

0

   8.   

Shared Dispositive Power

 

110,684,080

9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

110,684,080(1)

10.   

Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

 

☐

11.   

Percent of Class Represented By Amount in Row (9)

 

43.83%(2)

12.   

Type of Reporting Person (See Instructions)

 

PN

(1) Includes 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).

(2) Calculated based on 141,843,505 shares of Class A Common Stock outstanding as of November 7, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024, as increased by an additional 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).

1.   

Names of Reporting Persons

 

GTCR Co-Invest XI LP

2.   

Check The Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  (b) ☐

 

3.   

SEC Use Only

 

4.   

Citizenship or Place of Organization

 

Delaware

Number of Shares Beneficially  Owned By Each Reporting Person

With

    5.   

Sole Voting Power

 

0

   6.   

Shared Voting Power

 

110,684,080

   7.   

Sole Dispositive Power

 

0

   8.   

Shared Dispositive Power

 

110,684,080

9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

110,684,080(1)

10.   

Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

 

☐

11.   

Percent of Class Represented By Amount in Row (9)

 

43.83%(2)

12.   

Type of Reporting Person (See Instructions)

 

PN

 

(1)

Includes 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).

(2)

Calculated based on 141,843,505 shares of Class A Common Stock outstanding as of November 7, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024, as increased by an additional 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).

1.   

Names of Reporting Persons

 

GTCR Partners XI/A&C LP

2.   

Check The Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  (b) ☐

 

3.   

SEC Use Only

 

4.   

Citizenship or Place of Organization

 

Delaware

Number of Shares Beneficially  Owned By Each Reporting Person

With

    5.   

Sole Voting Power

 

0

   6.   

Shared Voting Power

 

20,150,005

   7.   

Sole Dispositive Power

 

0

   8.   

Shared Dispositive Power

 

20,150,005

9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

20,150,005

10.   

Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

 

☐

11.   

Percent of Class Represented By Amount in Row (9)

 

7.98%(1)

12.   

Type of Reporting Person (See Instructions)

 

PN

 

(1)

Calculated based on 141,843,505 shares of Class A Common Stock outstanding as of November 7, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024, as increased by an additional 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).

1.   

Names of Reporting Persons

 

GTCR Partners XI/B LP

2.   

Check The Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  (b) ☐

 

3.   

SEC Use Only

 

4.   

Citizenship or Place of Organization

 

Delaware

Number of Shares Beneficially  Owned By Each Reporting Person

With

    5.   

Sole Voting Power

 

0

   6.   

Shared Voting Power

 

110,684,080

   7.   

Sole Dispositive Power

 

0

   8.   

Shared Dispositive Power

 

110,684,080

9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

110,684,080(1)

10.   

Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

 

☐

11.   

Percent of Class Represented By Amount in Row (9)

 

43.83%(2)

12.   

Type of Reporting Person (See Instructions)

 

PN

 

(1)

Includes 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).

(2)

Calculated based on 141,843,505 shares of Class A Common Stock outstanding as of November 7, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024, as increased by an additional 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).

1.   

Names of Reporting Persons

 

GTCR Investment XI LLC

2.   

Check The Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  (b) ☐

 

3.   

SEC Use Only

 

4.   

Citizenship or Place of Organization

 

Delaware

Number of Shares Beneficially  Owned By Each Reporting Person

With

    5.   

Sole Voting Power

 

0

   6.   

Shared Voting Power

 

130,834,085

   7.   

Sole Dispositive Power

 

0

   8.   

Shared Dispositive Power

 

130,834,085

9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

130,834,085(1)

10.   

Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

 

☐

11.   

Percent of Class Represented By Amount in Row (9)

 

51.81%(2)

12.   

Type of Reporting Person (See Instructions)

 

OO

 

(1)

Includes 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).

(2)

Calculated based on 141,843,505 shares of Class A Common Stock outstanding as of November 7, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024, as increased by an additional 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).

Item 1(a).

Name of Issuer

Maravai LifeSciences Holdings, Inc. (the “Issuer”)

 

Item 1(b).

Address of the Issuer’s Principal Executive Offices

10770 Wateridge Circle, Suite 200

San Diego, CA 92121

 

Item 2(a).

Names of Persons Filing

This Amendment No. 3 to Schedule 13G is being jointly filed by the entities and persons listed below, each of which are collectively referred to herein as the “Reporting Persons”:

 

  (i)

Maravai Life Sciences Holdings 2, LLC (“MLSH 2”)

 

  (ii)

Maravai Life Sciences Holdings, LLC (“MLSH 1” and collectively with MLSH 2, the “MLSH Entities”)

 

  (iii)

GTCR Fund XI/C LP

 

  (iv)

GTCR Fund XI/B LP

 

  (v)

GTCR Co-Invest XI LP

 

  (vi)

GTCR Partners XI/A&C LP

 

  (vii)

GTCR Partners XI/B LP

 

  (viii)

GTCR Investment XI LLC

The Reporting Persons previously entered into an Agreement Regarding the Joint Filing of Schedule 13G, dated February 11, 2021, pursuant to which the Reporting Persons agreed to file the Schedule 13G and any amendments thereto jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

 

Item 2(b).

Address of the Principal Business Office, or if none, Residence

c/o GTCR, LLC

300 North LaSalle Street, Suite 5600

Chicago, IL 60654

 

Item 2(c).

Citizenship

See responses to Item 4 on each cover page.

 

Item 2(d).

Title of Class of Securities

Class A common stock, par value $0.01 per share.

 

Item 2(e).

CUSIP Number

56600D 107

 

Item 3.

If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a (n):

Not Applicable

 

Item 4.

Ownership

 

  (a)

Amount beneficially owned:

See responses to Item 9 on each cover page.

 

  (b)

Percent of Class:

See responses to Item 11 on each cover page.

  (c)

Number of shares as to which the Reporting Person has:

 

  (i)

Sole power to vote or to direct the vote:

See responses to Item 5 on each cover page.

 

  (ii)

Shared power to vote or to direct the vote:

See responses to Item 6 on each cover page.

 

  (iii)

Sole power to dispose or to direct the disposition of:

See responses to Item 7 on each cover page.

 

  (iv)

Shared power to dispose or to direct the disposition of:

See responses to Item 8 on each cover page.

Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, MLSH 1 is entitled at its option to exchange Common Units (together with an equal number of shares of Class B Common Stock) for shares of Class A Common Stock on a one-for-one basis. MLSH 1 directly holds 110,684,080 Common Units and MLSH 2 directly holds 20,150,005 shares of Class A Common Stock.

MLSH 1 and MLSH 2 are each managed by a board of managers. GTCR Fund XI/C LP controls the board of managers of MLSH 2. GTCR Fund XI/B LP and GTCR Co-Invest XI LP control the board of managers of MLSH 1. GTCR Partners XI/A&C LP is the general partner of GTCR Fund XI/C LP. GTCR Partners XI/B LP is the general partner of GTCR Fund XI/B LP. GTCR Investment XI LLC is the general partner of each of GTCR Co-Invest XI LP, GTCR Partners XI/A&C LP and GTCR Partners XI/B LP. GTCR Investment XI LLC is managed by a board of managers (the “GTCR Board of Managers”) consisting of Mark M. Anderson, Aaron D. Cohen, Sean L. Cunningham, David A. Donnini, Constantine S. Mihas and Collin E. Roche, and no single person has voting or dispositive authority over the shares of Class A Common Stock held directly by MLSH 2 and MLSH 1, respectively. Each of GTCR Partners XI/A&C LP, GTCR Investment XI LLC and the GTCR Board of Managers may be deemed to share beneficial ownership of the shares of Class A Common Stock held of record by MLSH 2, and each of GTCR Partners XI/B LP, GTCR Investment XI LLC and the GTCR Board of Managers may be deemed to share beneficial ownership of the shares held of record by MLSH 1 and each of the individual members of the GTCR Board of Managers disclaims beneficial ownership of the shares of Class A Common Stock held of record by MLSH 1 and MLSH 2 and this statement shall not be construed as an admission that any of such individual members or any of the Reporting Persons are, for purposes of Section 13(d) or 13(g) of the Act, beneficial owners of the reported securities.

 

Item 5.

Ownership of Five Percent or Less of a Class

Not Applicable.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not Applicable.

 

Item 7

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

Not Applicable.

 

Item 8.

Identification and Classification of Members of the Group

Not Applicable.

Item 9.

Notice of Dissolution of Group

Not Applicable.

 

Item 10.

Certification

Not Applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 13, 2024

 

MARAVAI LIFE SCIENCES HOLDINGS, LLC
By:  

/s/ Kevin Herde

Name: Kevin Herde

Title: Chief Financial Officer

MARAVAI LIFE SCIENCES HOLDINGS 2, LLC
By:  

/s/ Kevin Herde

Name: Kevin Herde

Title: Chief Financial Officer

GTCR FUND XI/C LP

By: GTCR Partners XI/A&C LP

Its: General Partner

By: GTCR Investment XI LLC

Its: General Partner

By:  

/s/ Jeffrey Wright

Name: Jeffrey Wright

Title: Chief Legal Officer

GTCR FUND XI/B LP

By: GTCR Partners XI/B LP

Its: General Partner

By: GTCR Investment XI LLC

Its: General Partner

By:  

/s/ Jeffrey Wright

Name: Jeffrey Wright

Title: Chief Legal Officer

GTCR PARTNERS XI/A&C LP

By: GTCR Investment XI LLC

Its: General Partner

By:  

/s/ Jeffrey Wright

Name: Jeffrey Wright

Title: Chief Legal Officer

GTCR CO-INVEST XI LP
By: GRCR Investment XI LLC
Its: General Partner
By:  

/s/ Jeffrey Wright

Name: Jeffrey Wright
Title: Chief Legal Officer
GTCR PARTNERS XI/B LP
By: GTCR Investment XI LLC
Its: General Partner
By:  

/s/ Jeffrey Wright

Name: Jeffrey Wright
Title: Chief Legal Officer
GTCR INVESTMENT XI LLC
By:  

/s/ Jeffrey Wright

Name: Jeffrey Wright
Title: Chief Legal Officer

EXHIBIT LIST

 

Exhibit A    Joint Filing Agreement, dated as of February 11, 2021, by and among the Reporting Persons (incorporated herein by reference to Exhibit A of the statement on Schedule 13G filed by the Reporting Persons on February 11, 2021).
Get the next $MRVI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MRVI

DatePrice TargetRatingAnalyst
2/26/2025$9.00 → $3.00Outperform → Neutral
Robert W. Baird
12/19/2024Neutral
Guggenheim
12/5/2024$4.25Neutral → Sell
Goldman
11/14/2024Peer Perform
Wolfe Research
11/8/2024Outperform → Mkt Perform
William Blair
8/28/2024$10.00Overweight
Wells Fargo
8/13/2024$11.00 → $10.00Overweight → Equal-Weight
Morgan Stanley
4/10/2024$15.00Buy
Craig Hallum
More analyst ratings

$MRVI
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Maravai Lifesciences Reports Fourth Quarter and Full Year 2024 Financial Results

    SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2024, together with other business updates. The company also expects to file its Annual Report on Form 10-K for the year ended December 31, 2024, with the Securities and Exchange Commission today. Upon filing, a copy of the annual report will be available on Maravai's website, www.maravai.com, by selecting "Investors" and then "SEC Filings." Key Financial Results: Quarterly revenue of $56.6 million, Ne

    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Maravai LifeSciences Postpones its Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

    SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that it is postponing its previously announced earnings release and call scheduled for February 25, 2025. It also announced that it intends to file a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission and will delay the filing its annual report on Form 10-K for the fiscal year ended December 31, 2024 (the "2024 Form 10-K"). Maravai intends to hold its postponed earnings call and to file the 2024 Form 10-K as soon as practicable and on or

    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Maravai LifeSciences Completes Acquisition of the DNA and RNA Business of Officinae Bio

    Officinae Bio's AI-driven sequence optimization expands Maravai's family of brands, enabling rapid, cost-effective nucleic acid therapy development Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has completed its previously announced acquisition of Officinae Bio's DNA and RNA business. This acquisition combines Officinae Bio's AI-enabled mRNA design platforms with Maravai and TriLink BioTechnologies' leading drug substance manufacturing capabilities, providing customers comprehensive expertise and novel technologies for quick, calculated progression through the mRNA sequence-op

    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MRVI
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MRVI
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$MRVI
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MRVI
 SEC Filings

See more

$MRVI
 Leadership Updates

Live Leadership Updates

See more

  • Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

    SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have

    $BDX
    $FTRE
    $MRVI
    Medical/Dental Instruments
    Health Care
    Medical Specialities
    Biotechnology: Pharmaceutical Preparations

  • Maravai LifeSciences Appoints Trey Martin to Board of Directors

    SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that its CEO William "Trey" Martin, III has been appointed to the Company's Board of Directors, effective July 31, 2024. This strategic appointment underscores Martin's commitment to innovation, leadership capabilities, and deep industry knowledge. "We are thrilled to welcome Trey to our Board of Directors," said Carl Hull, Maravai's co-founder and Executive Chair of its Board of Directors. "Trey's extensive experience and depth of knowledge will bring valuable perspectives and enrich our collective

    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Maravai LifeSciences Announces Completion of Planned CEO Leadership Transition

    William "Trey" Martin, III assumes the role of Maravai's CEO Carl Hull to continue to serve as Executive Chairman SAN DIEGO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that William "Trey" Martin, III has assumed the role of Chief Executive Officer (CEO) of Maravai LifeSciences effective July 27, 2023, consistent with the Company's previously announced CEO succession plan. Carl Hull, Maravai's co-founder and prior interim CEO, will continue to serve as Maravai's Executive Chairman of the Board. "We are thri

    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MRVI
 Financials

Live finance-specific insights

See more

  • Maravai Lifesciences Reports Fourth Quarter and Full Year 2024 Financial Results

    SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2024, together with other business updates. The company also expects to file its Annual Report on Form 10-K for the year ended December 31, 2024, with the Securities and Exchange Commission today. Upon filing, a copy of the annual report will be available on Maravai's website, www.maravai.com, by selecting "Investors" and then "SEC Filings." Key Financial Results: Quarterly revenue of $56.6 million, Ne

    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Maravai LifeSciences Postpones its Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

    SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that it is postponing its previously announced earnings release and call scheduled for February 25, 2025. It also announced that it intends to file a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission and will delay the filing its annual report on Form 10-K for the fiscal year ended December 31, 2024 (the "2024 Form 10-K"). Maravai intends to hold its postponed earnings call and to file the 2024 Form 10-K as soon as practicable and on or

    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Maravai LifeSciences Acquires Assets and Intellectual Property from Molecular Assemblies

    Molecular Assemblies proprietary Fully Enzymatic SynthesisTM technology to enhance mRNA and oligonucleotide manufacturing capabilities within the TriLink BioTechnologies business Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today its acquisition of intellectual property and relevant assets from Molecular Assemblies (MAI). The acquisition will expand Maravai and TriLink BioTechnologies' ability to enable customers to develop next-generation mRNA and CRISPR nucleic acid-based therapies. "Molecular Assemblies is the original leader in enzymatic oligo synthesis, with strong foundational IP.

    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MRVI
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more